- Innovation alone is no longer enough in biopharma<p>In biopharma, the next edge may come from the systems that turn discovery into scale.</p>BioPharma Dive · 1mo ago↗ source
- Precision under pressure: Logistic solutions for nuclear medicine scalability<p>Racing the clock: How precision logistics deliver life-saving nuclear medicine.</p>BioPharma Dive · 1mo ago↗ source
- #ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsBoehringer Ingelheim’s obesity asset survodutide, which it licensed from Zealand Pharma, has shown high rates of discontinuations in its Phase 3 obesity study. In April, data from the SYNCHRONIZE…Endpoints · 1mo ago↗ source